Teysuno
What Teysuno is used for
Teysuno is indicated in adults: - for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1). - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Teysuno
- Active substance
- tegafur;gimeracil;oteracil
- Disease area
- Stomach Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01BC53
- Marketing authorisation holder
- Nordic Group B.V.
- Authorised in the EU since
- 2011
Official information
In India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Teysuno used for?
Teysuno is indicated in adults: - for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1). - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.
What is the active substance in Teysuno?
Teysuno contains tegafur;gimeracil;oteracil.
Who makes Teysuno?
The EU marketing authorisation holder is Nordic Group B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU